KIT and melanoma: Despite the clear capacity of small-molecule inhibitors to target and inhibit KIT mutants in melanoma cell lines in culture, only infrequent tumor responses of typically minimal durability have been observed in clinical trials treating KIT-mutant melanoma patients with KIT inhibitors [10,15,16,17,18,19].